Alaska Medicaid Pharmacy and Therapeutics Committee Meeting November 15, 2024

(Please note, this meeting will be available via teleconference only)

Please register for the meeting by using the link below:

 $\underline{https://events.teams.microsoft.com/event/e9e0105b-7481-4a5a-ac9c-954c2fa99fc5@34c95ba7-5ec6-4527-bc5e-b33b58104992}$

If you are calling in only through the webinar:

*6 to Toggle mute/unmute and *5 to raise/lower hand

After registering, you will receive a confirmation email containing information about joining the webinar.

Agenda

Public Call In toll free: 1-844-730-9010 Access code: 783 235 074#

Call to Order – Chair
Roll Call
8:00 am
8:05 am

3. Public Comment

The Department's methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are *new classes/new drugs* and **Blue** are classes where **new information exists and industry testimony will be taken. Classes shown in **Green** are classes with no significant changes have been noted and no industry testimony will be taken.

4. Class review, discussion & vote.

AK Treatment Class	Drug Class	Status
Central Nervous System	Alzheimer's Agents	RED**
	Anticonvulsants	BLUE**
	Antidepressants	GREEN
	Antipsychotics – Atypical	BLUE**
	Multiple Sclerosis Agents	BLUE**
	Sedative Hypnotics	GREEN
	Stimulants and Related Agents	BLUE**
Substance Dependence	Opioid Dependence	BLUE**
	Opioid Reversal Agents	BLUE**
	Smoking Cessation Products	GREEN
Analgesics	Antimigraine Agents	GREEN
	Analgesics, Opioid Long-acting	GREEN
	Analgesics, Opioid Short-acting	BLUE**
	Neuropathic Pain	GREEN
	NSAIDS	BLUE**
	Restless Leg Syndrome (RLS)	GREEN
	Skeletal Muscle Relaxants	GREEN

^{**}New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.

	Antibiotics, Inhaled	GREEN
Cystic Fibrosis	CFTR Potentiator Agents	GREEN
	Pancreatic Enzymes	GREEN
Antiviral Monoclonal Antibodies	Respiratory Syncytial Virus (RSV)	GREEN

- 5. **Break as needed** 15 minutes
- 6. Review minutes from previous meeting
- 7. Comments from Committee Members or Chair
- 8. Adjourn

Next Meeting Date: January 17, 2025